Mounjaro Side Effects: Delayed-Onset Adverse Events Explained

Which side effects actually arrive late?

Tirzepatide is a once-weekly GIP and GLP-1 receptor agonist. Mounjaro is approved to improve blood sugar in adults and children 10 and older with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes who are at high risk for these events [1]. It is not labeled for weight loss [1], so the body-composition substudy discussed below comes from the weight-management program for tirzepatide.

The label states that most nausea, vomiting and diarrhea reports occurred during dose escalation and decreased over time [1]. It also states that Mounjaro delays gastric emptying, with the largest delay after the first dose and an effect that diminishes over time [1].

The boxed warning covers thyroid C-cell tumors that were dose- and duration-dependent in rats, and it states that whether Mounjaro causes these tumors in humans is unknown [1].

Nausea, vomiting and diarrhea: most reports come during dose escalation

The Mounjaro label pools two placebo-controlled adult trials (SURPASS-1 and SURPASS-5): 235 patients received placebo and 237, 240 and 241 received 5, 10 and 15 mg once weekly, with a mean exposure of 36.6 weeks [1].

• Nausea: 4% on placebo versus 12%, 15% and 18% [1]
• Diarrhea: 9% versus 12%, 13% and 17% [1]
• Vomiting: 2% versus 5%, 5% and 9% [1]
• Decreased appetite: 1% versus 5%, 10% and 11% [1]
• Constipation: 1% versus 6%, 6% and 7% [1]
• Dyspepsia: 3% versus 8%, 8% and 5% [1]

Doses in each list run 5 mg, then 10 mg, then 15 mg. Any gastrointestinal reaction was reported by 20.4% of placebo patients versus 37.1%, 39.6% and 43.6% [1], and treatment was stopped for a GI reaction by 0.4% versus 3.0%, 5.4% and 6.6% [1]. Severe GI reactions occurred in 0.9% on placebo versus 1.3%, 0.4% and 1.2% [1]. Reflux was reported by 0.4% on placebo versus 1.7%, 2.5% and 1.7% [1]. Mounjaro is not recommended in patients with severe gastroparesis [1].

The label's statement that reports decreased over time names nausea, vomiting and diarrhea, not constipation [1]. The label also cautions that adverse reaction rates from different trials cannot be directly compared, because trials run under widely varying conditions. GI rates from the tirzepatide weight-management trials, which studied different populations, are therefore not directly comparable with these [1].

Gallbladder disease: what the label reports

Acute gallbladder disease — cholelithiasis, biliary colic and cholecystectomy — was reported by 0.6% of Mounjaro-treated adults and 0% of those on placebo in the adult placebo-controlled trials [1].

The label directs that if cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated [1].

Acute pancreatitis: what the label says

The label warns that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists or with Mounjaro [1]. It says to observe patients carefully after starting treatment for signs and symptoms, which may include persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, and to discontinue Mounjaro and begin appropriate management if pancreatitis is suspected [1].

Thyroid C-cell tumors: what the boxed warning covers

The boxed warning reports that in both male and female rats, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures, and that it is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans [1]. Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 [1].

The label asks that patients be told about the potential risk and about symptoms of thyroid tumors: a mass in the neck, difficulty swallowing, difficulty breathing, or persistent hoarseness [1]. Routine serum calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection, partly because of low test specificity and the high background rate of thyroid disease [1]. The rat tumors depended on both dose and duration of exposure; whether that carries over to humans is unknown [1].

Hair loss and the label

Hair loss does not appear in the Mounjaro label's adverse reaction text; the reactions it reports in at least 5% of treated patients are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain [1]. The Zepbound label, which covers tirzepatide at weight-management doses, does report hair loss: 4% to 5% of Zepbound patients versus 1% on placebo, associated with weight reduction and more frequent in women (7.1% of women versus 0.5% of men). Those Zepbound figures come from a different population and are not Mounjaro rates.

Lean mass: what the DXA substudy found

A body-composition substudy of the large weight-management trial scanned 160 participants with DXA at baseline and at week 72: 124 pooled tirzepatide doses and 36 placebo, 73% female, mean weight 102.5 kg [2]. Over 72 weeks, body weight fell 21.3% with tirzepatide versus 5.3% with placebo, fat mass fell 33.9% versus 8.2%, and lean mass fell 10.9% versus 2.6% [2].

About 75% of the weight lost was fat mass and about 25% was lean mass — and that split was the same in the placebo group [2]. This is a small substudy, and DXA does not separate muscle from other lean tissue, so it should not be read as a precise muscle-loss figure.

Kidney injury: reports tied to dehydration

The label describes postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, in patients treated with GLP-1 receptor agonists or Mounjaro, with most of the reported events occurring in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea [1]. It directs monitoring of renal function in patients reporting reactions that could lead to volume depletion, especially during dosage initiation and escalation [1].